TY - JOUR
T1 - Personalized cancer vaccines
T2 - Targeting the cancer mutanome
AU - Zhang, Xiuli
AU - Sharma, Piyush K.
AU - Peter Goedegebuure, S.
AU - Gillanders, William E.
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2017/2/15
Y1 - 2017/2/15
N2 - The development of next generation sequencing technologies has revolutionized our understanding of how specific genetic events contribute to cancer initiation and progression. Dramatic improvements in instrument design and efficiency, combined with significant cost reductions has permitted a systematic analysis of the mutational landscape in a variety of cancer types. At the same time, a detailed map of the cancer mutanome in individual cancers offers a unique opportunity to develop personalized cancer vaccine strategies targeting neoantigens. Recent studies in both preclinical models and human cancer patients demonstrate that neoantigens (1) are important targets following checkpoint inhibition therapy, (2) have been identified as the target of adoptive T cell therapies, and (3) can be successfully targeted with personalized vaccines. Taken together, these observations provide strong rationale for the clinical translation of personalized cancer vaccines.
AB - The development of next generation sequencing technologies has revolutionized our understanding of how specific genetic events contribute to cancer initiation and progression. Dramatic improvements in instrument design and efficiency, combined with significant cost reductions has permitted a systematic analysis of the mutational landscape in a variety of cancer types. At the same time, a detailed map of the cancer mutanome in individual cancers offers a unique opportunity to develop personalized cancer vaccine strategies targeting neoantigens. Recent studies in both preclinical models and human cancer patients demonstrate that neoantigens (1) are important targets following checkpoint inhibition therapy, (2) have been identified as the target of adoptive T cell therapies, and (3) can be successfully targeted with personalized vaccines. Taken together, these observations provide strong rationale for the clinical translation of personalized cancer vaccines.
KW - Cancer vaccine
KW - Genome sequencing
KW - Neoantigen
KW - Personalized
UR - http://www.scopus.com/inward/record.url?scp=84979496951&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2016.05.073
DO - 10.1016/j.vaccine.2016.05.073
M3 - Article
C2 - 27449681
AN - SCOPUS:84979496951
SN - 0264-410X
VL - 35
SP - 1094
EP - 1100
JO - Vaccine
JF - Vaccine
IS - 7
ER -